Gabelli & Co Investment Advisers’s Aimmune Therapeutics AIMT Stock Holding History

Gabelli & Co Investment Advisers’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-501,719	Closed	-$17.3M	–	392
2020 Q3	$17.3M	Buy	+501,719	New	+$10.7M	3.11%	8

Gabelli & Co Investment Advisers's AIMT Position: Q4 2020 in Review

Gabelli & Co Investment Advisers sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 501,719 shares — an estimated $17.3M sold.

Gabelli & Co Investment Advisers first reported a position in AIMT in Q3 2020 and held it in 1 quarter. The position peaked at $17.3M in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

Gabelli & Co Investment Advisers reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
Gabelli & Co Investment Advisers sold 501,719 Aimmune Therapeutics shares in Q4 2020, an estimated $17.3M.
Gabelli & Co Investment Advisers first reported a position in Aimmune Therapeutics in Q3 2020 and held it in 1 quarter.
Gabelli & Co Investment Advisers's Aimmune Therapeutics position peaked at $17.3M in Q3 2020.
0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Gabelli & Co Investment Advisers's 13F filing for Q4 2020, filed 5 Feb 2021.